ES2762501T8 - Composición de anticuerpo y sistema amortiguador para la misma - Google Patents
Composición de anticuerpo y sistema amortiguador para la mismaInfo
- Publication number
- ES2762501T8 ES2762501T8 ES14730479T ES14730479T ES2762501T8 ES 2762501 T8 ES2762501 T8 ES 2762501T8 ES 14730479 T ES14730479 T ES 14730479T ES 14730479 T ES14730479 T ES 14730479T ES 2762501 T8 ES2762501 T8 ES 2762501T8
- Authority
- ES
- Spain
- Prior art keywords
- buffer system
- antibody composition
- system therefor
- therefor
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007853 buffer solution Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Inorganic Chemistry (AREA)
- Ceramic Engineering (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1309759.7A GB2516808A (en) | 2013-05-31 | 2013-05-31 | Antibody composition and buffer system therefor |
PCT/EP2014/061281 WO2014191560A1 (en) | 2013-05-31 | 2014-05-30 | Antibody composition and buffer system therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2762501T3 ES2762501T3 (es) | 2020-05-25 |
ES2762501T8 true ES2762501T8 (es) | 2020-06-18 |
Family
ID=48805557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES14730479T Active ES2762501T3 (es) | 2013-05-31 | 2014-05-30 | Composición de anticuerpo y sistema amortiguador para la misma |
Country Status (9)
Country | Link |
---|---|
US (1) | US11046753B2 (es) |
EP (1) | EP3003385B1 (es) |
JP (2) | JP2016530216A (es) |
CN (1) | CN105592860B (es) |
AU (1) | AU2014273034B2 (es) |
DK (1) | DK3003385T3 (es) |
ES (1) | ES2762501T3 (es) |
GB (2) | GB2516808A (es) |
WO (1) | WO2014191560A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3380525T3 (da) | 2015-11-25 | 2024-01-29 | Immunogen Inc | Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf |
CN111896752A (zh) * | 2020-08-11 | 2020-11-06 | 上海捷门生物技术有限公司 | 一种适用于多种poct类仪器的c-反应蛋白试剂盒 |
CN113671188A (zh) * | 2021-08-10 | 2021-11-19 | 江南大学 | 一种检测贝类食品中河豚毒素的时间分辨免疫定量试纸条 |
EP4218562A1 (en) | 2022-01-28 | 2023-08-02 | Charité - Universitätsmedizin Berlin | Real-time breath antigen detection system and method thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0516873A1 (en) | 1991-06-06 | 1992-12-09 | THE STATE of ISRAEL Atomic Energy Commission Soreq Nuclear Research Center | A method and kit for protein labelling with 99 mTC |
DE69915204T2 (de) * | 1998-08-17 | 2004-07-29 | Pfizer Products Inc., Groton | Stabilisierte Proteinzusammensetzung |
CA2604840A1 (en) * | 2005-04-18 | 2006-10-26 | Xtl Biopharmaceuticals Ltd. | Stabilized anti-hepatitis b (hbv) antibody formulations |
US7790679B2 (en) * | 2005-08-05 | 2010-09-07 | Amgen Inc. | Pharmaceutical formulations |
GB2446088B (en) * | 2005-12-12 | 2010-10-20 | Innova Biosciences Ltd | Production of conjugates |
WO2007074880A1 (ja) | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
CA2672902C (en) * | 2006-12-21 | 2012-11-27 | Amgen Inc. | Formulations |
JP5476376B2 (ja) * | 2008-07-16 | 2014-04-23 | ラジオメーター・メディカル・アー・ペー・エス | 高性能固相 |
JP2011241206A (ja) * | 2010-04-23 | 2011-12-01 | Arkray Inc | 標識抗体の安定化方法 |
ES2671347T3 (es) * | 2010-06-21 | 2018-06-06 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para purificar una proteína que utiliza un aminoácido |
US8877892B2 (en) * | 2011-03-15 | 2014-11-04 | Innova Biosciences Limited | Conjugation reactions |
WO2012123488A1 (en) * | 2011-03-16 | 2012-09-20 | F. Hoffmann-La Roche Ag | Ion exchange chromatography with improved selectivity for the separation of polypeptide monomers, aggregates and fragments by modulation of the mobile phase |
KR20120128440A (ko) | 2011-05-17 | 2012-11-27 | 삼성전자주식회사 | 표적 물질 검출용 키트 및 이를 이용한 표적 물질 검출 방법 |
-
2013
- 2013-05-31 GB GB1309759.7A patent/GB2516808A/en not_active Withdrawn
-
2014
- 2014-05-30 CN CN201480043061.4A patent/CN105592860B/zh active Active
- 2014-05-30 US US14/894,828 patent/US11046753B2/en active Active
- 2014-05-30 WO PCT/EP2014/061281 patent/WO2014191560A1/en active Application Filing
- 2014-05-30 JP JP2016516187A patent/JP2016530216A/ja active Pending
- 2014-05-30 EP EP14730479.4A patent/EP3003385B1/en active Active
- 2014-05-30 DK DK14730479.4T patent/DK3003385T3/da active
- 2014-05-30 AU AU2014273034A patent/AU2014273034B2/en active Active
- 2014-05-30 ES ES14730479T patent/ES2762501T3/es active Active
- 2014-05-30 GB GB1522774.7A patent/GB2530217A/en not_active Withdrawn
-
2019
- 2019-09-09 JP JP2019163553A patent/JP2020007343A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN105592860B (zh) | 2021-02-02 |
AU2014273034A1 (en) | 2016-01-28 |
GB2516808A (en) | 2015-02-11 |
US20160122416A1 (en) | 2016-05-05 |
JP2020007343A (ja) | 2020-01-16 |
GB2530217A (en) | 2016-03-16 |
GB201522774D0 (en) | 2016-02-03 |
ES2762501T3 (es) | 2020-05-25 |
CN105592860A (zh) | 2016-05-18 |
GB201309759D0 (en) | 2013-07-17 |
JP2016530216A (ja) | 2016-09-29 |
EP3003385B1 (en) | 2019-09-18 |
WO2014191560A1 (en) | 2014-12-04 |
US11046753B2 (en) | 2021-06-29 |
EP3003385A1 (en) | 2016-04-13 |
DK3003385T3 (da) | 2020-01-06 |
AU2014273034B2 (en) | 2019-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2016001646A1 (es) | Anticuerpos y fragmentos anti-vista | |
CL2016001102A1 (es) | Anticuerpos anti-claudina novedosos y métodos de uso. | |
CL2016000680A1 (es) | Formulaciones de anticuerpos anti-pdl1. | |
DK2970460T3 (da) | Anti-IL-33-antistoffer og anvendelser deraf | |
CL2015001924A1 (es) | Anticuerpos anti-pdgfr-beta y usos relacionados. | |
BR112016011233A2 (pt) | Sistema e método para seleção de esperma | |
BR112015027522A2 (pt) | sistema e método de publicidade | |
DK3736291T5 (da) | Anti-FCRH5-antistoffer | |
DK3026062T3 (da) | Anti-pd-1-antistof og anvendelse deraf | |
BR112015023547A2 (pt) | sistema de posicionamento inteligente e métodos para o mesmo | |
BR112015029662A2 (pt) | sistema, e método | |
BR112015012032A2 (pt) | sistema e método para recompensar viajantes | |
DK3708583T3 (da) | Ikke-fucosylerede anti-fgfr2iiib-antistoffer | |
BR112015003838A2 (pt) | formulações de anticorpo e proteína | |
BR112015022167A2 (pt) | dispositivos, sistemas e métodos para preparação de amostras | |
DK3052522T3 (da) | Anti-sox 10 antistofsystemer og -fremgangsmåder | |
HK1223112A1 (zh) | 抗- -α/ 雙靶向抗體及其應用 | |
BR112014026357A2 (pt) | composição e sistema | |
DK3068800T3 (da) | FcRn-specifikke antistoffer | |
BR112016000304A2 (pt) | Sistema e método | |
BR112015028506A2 (pt) | programa, sistema para processamento de informação e dispositivo para processamento de informação | |
DK3065774T3 (da) | Anti-CCL17-antistoffer | |
FI20135347A (fi) | Kulkutie ja menetelmä sen valmistamiseksi | |
ES2762501T8 (es) | Composición de anticuerpo y sistema amortiguador para la misma | |
ES1228373Y (es) | Sistema de ventanas |